Leading university:
University of Milan
Project leader:
Assoc. Prof. Laura Fumagalli
Contact:
[e-mail]
Flagship:
Flagship 1: Urban Health and Demographic Change
Participating universities:
Charles University, Heidelberg University, University of Geneva, University of Milan
The INTERCONNECT project aims to explore the synergistic effects of inhibiting DPP-IV and CA isoforms II and V on glucose homeostasis, advancing therapeutic strategies for treating type 2 diabetes (T2DM). The research includes the synthesis and analysis of a novel 'tool compound' and its impact on diabetes-related tissues. The project will synthesize the compound and assess its impact using various experimental models, including pancreatic β-cells and kidney proximal tubules cells. The results and developments will be disseminated through scientific publications and presentations at national and international conferences. The project aims to enhance the understanding of T2DM and improve patient outcomes by potentially developing a new therapeutic approach that combines the inhibition of both DPP-IV and CA.